USD 0.49
(-3.35%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 19.97 Million USD | -0.38% |
2022 | 20.04 Million USD | 1.45% |
2021 | 19.76 Million USD | -1.77% |
2020 | 20.11 Million USD | 18.84% |
2019 | 16.93 Million USD | 18.9% |
2018 | 14.23 Million USD | -71.96% |
2017 | 50.77 Million USD | 2.96% |
2016 | 49.31 Million USD | 28.04% |
2015 | 38.51 Million USD | -77.16% |
2014 | 168.64 Million USD | 22.39% |
2013 | 137.79 Million USD | 32.53% |
2012 | 103.96 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 9.54 Million USD | -54.38% |
2024 Q1 | 20.91 Million USD | 4.72% |
2023 Q2 | 23.53 Million USD | 7.15% |
2023 FY | 19.97 Million USD | -0.38% |
2023 Q1 | 21.96 Million USD | 9.54% |
2023 Q4 | 19.97 Million USD | 4.03% |
2023 Q3 | 19.19 Million USD | -18.42% |
2022 Q4 | 20.04 Million USD | -12.85% |
2022 Q3 | 23 Million USD | 5.3% |
2022 FY | 20.04 Million USD | 1.45% |
2022 Q1 | 21.38 Million USD | 8.2% |
2022 Q2 | 21.84 Million USD | 2.17% |
2021 Q2 | 20.9 Million USD | -3.36% |
2021 Q3 | 22.17 Million USD | 6.05% |
2021 Q4 | 19.76 Million USD | -10.87% |
2021 FY | 19.76 Million USD | -1.77% |
2021 Q1 | 21.63 Million USD | 7.53% |
2020 Q1 | 18.39 Million USD | 8.64% |
2020 Q4 | 20.11 Million USD | -10.55% |
2020 Q3 | 22.49 Million USD | 5.42% |
2020 FY | 20.11 Million USD | 18.84% |
2020 Q2 | 21.33 Million USD | 16.0% |
2019 Q1 | 12.97 Million USD | -8.88% |
2019 Q2 | 18.89 Million USD | 45.67% |
2019 Q4 | 16.93 Million USD | -12.07% |
2019 Q3 | 19.25 Million USD | 1.87% |
2019 FY | 16.93 Million USD | 18.9% |
2018 Q1 | 12.06 Million USD | -76.24% |
2018 FY | 14.23 Million USD | -71.96% |
2018 Q4 | 14.23 Million USD | 0.73% |
2018 Q3 | 14.13 Million USD | 11.84% |
2018 Q2 | 12.63 Million USD | 4.77% |
2017 Q3 | 47.68 Million USD | -1.03% |
2017 FY | 50.77 Million USD | 2.96% |
2017 Q4 | 50.77 Million USD | 6.49% |
2017 Q2 | 48.17 Million USD | -0.75% |
2017 Q1 | 48.54 Million USD | -1.57% |
2016 Q1 | 40.34 Million USD | 4.76% |
2016 Q3 | 48.52 Million USD | 3.41% |
2016 Q2 | 46.92 Million USD | 16.3% |
2016 Q4 | 49.31 Million USD | 1.63% |
2016 FY | 49.31 Million USD | 28.04% |
2015 FY | 38.51 Million USD | -77.16% |
2015 Q1 | 37.3 Million USD | -77.88% |
2015 Q2 | 36.93 Million USD | -0.99% |
2015 Q4 | 38.51 Million USD | 4.86% |
2015 Q3 | 36.73 Million USD | -0.54% |
2014 Q2 | 44.08 Million USD | 0.0% |
2014 FY | 168.64 Million USD | 22.39% |
2014 Q4 | 168.64 Million USD | 330.11% |
2014 Q1 | - USD | -100.0% |
2014 Q3 | 39.21 Million USD | -11.05% |
2013 FY | 137.79 Million USD | 32.53% |
2013 Q1 | - USD | 0.0% |
2013 Q4 | 137.79 Million USD | 0.0% |
2012 FY | 103.96 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Akoya Biosciences, Inc. | 126.59 Million USD | 84.224% |
AngioDynamics, Inc. | 112.08 Million USD | 82.181% |
AtriCure, Inc. | 147.76 Million USD | 86.484% |
Azenta, Inc. | 351.22 Million USD | 94.314% |
BioLife Solutions, Inc. | 75.05 Million USD | 73.389% |
The Cooper Companies, Inc. | 4.1 Billion USD | 99.514% |
Daxor Corporation | 858.75 Thousand USD | -2225.684% |
Ekso Bionics Holdings, Inc. | 16.31 Million USD | -22.437% |
Femasys Inc. | 9.4 Million USD | -112.395% |
GlucoTrack, Inc. | 1.7 Million USD | -1069.321% |
Harvard Bioscience, Inc. | 64.29 Million USD | 68.935% |
Hologic, Inc. | 4.02 Billion USD | 99.504% |
ICU Medical, Inc. | 2.25 Billion USD | 99.114% |
Intuitive Surgical, Inc. | 2.04 Billion USD | 99.023% |
KORU Medical Systems, Inc. | 8.1 Million USD | -146.349% |
LeMaitre Vascular, Inc. | 48.87 Million USD | 59.139% |
Innovative Eyewear, Inc. | 659.93 Thousand USD | -2926.354% |
Innovative Eyewear, Inc. | 659.93 Thousand USD | -2926.354% |
Masimo Corporation | 1.67 Billion USD | 98.809% |
Microbot Medical Inc. | 3.82 Million USD | -422.007% |
Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | 20.359% |
Merit Medical Systems, Inc. | 1.12 Billion USD | 98.222% |
Nephros, Inc. | 3.5 Million USD | -470.14% |
NovoCure Limited | 783.63 Million USD | 97.451% |
NEXGEL, Inc. | 4.78 Million USD | -317.039% |
NEXGEL, Inc. | 4.78 Million USD | -317.039% |
Singular Genomics Systems, Inc. | 86.46 Million USD | 76.901% |
OraSure Technologies, Inc. | 52.17 Million USD | 61.72% |
Pro-Dex, Inc. | 23.34 Million USD | 14.441% |
Pulse Biosciences, Inc. | 16.44 Million USD | -21.455% |
Predictive Oncology Inc. | 6.14 Million USD | -224.987% |
Precision Optics Corporation, Inc. | 6.84 Million USD | -191.784% |
QuidelOrtho Corporation | 3.55 Billion USD | 99.439% |
Repligen Corporation | 853.2 Million USD | 97.659% |
Sanara MedTech Inc. | 29.28 Million USD | 31.797% |
STAAR Surgical Company | 102.73 Million USD | 80.56% |
Sharps Technology, Inc. | 3.85 Million USD | -418.083% |
Utah Medical Products, Inc. | 7.14 Million USD | -179.524% |
DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.51% |
Jin Medical International Ltd. | 8.92 Million USD | -123.792% |